Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Inflammation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1460431

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

Provisionally accepted
Chenghui Cao Chenghui Cao 1,2Wenwu Liu Wenwu Liu 1Xin Guo Xin Guo 1Shuwei Weng Shuwei Weng 1Yang Chen Yang Chen 1Yonghong Luo Yonghong Luo 1Shuai Wang Shuai Wang 1Botao Zhu Botao Zhu 1,2Yuxuan Liu Yuxuan Liu 1,2Daoquan Peng Daoquan Peng 1*
  • 1 Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
  • 2 Xiangya School of Medicine, Central South University, Changsha, Hunan Province, China

The final, formatted version of the article will be published soon.

    Background: Non-alcoholic steatohepatitis (NASH) Metabolic dysfunctionassociated steatohepatitis (MASH) is a highly prevalent liver disease globally, with a significant risk of progressing to cirrhosis and even liver cancer. Efferocytosis, a process implicated in a broad spectrum of chronic inflammatory disorders, has been reported to be associated with the pathogenesis of MASH; however, its precise role remains obscure. Thus, we aimed to identify and validate efferocytosis linked signatures for detection of MASH.We retrieved gene expression patterns of MASH from the GEO database and then focused on assessing the differential expression of efferocytosisrelated genes (EFRGs) between MASH and control groups. This analysis was followed by a series of in-depth investigations, including protein-protein interaction (PPI), correlation analysis, and functional enrichment analysis, to uncover the molecular interactions and pathways at play. To screen for biomarkers for diagnosis, we applied machine learning algorithm to identify hub genes and constructed a clinical predictive model. Additionally, we conducted immune infiltration and single-cell transcriptome analyses in both MASH and control samples, providing insights into the immune cell landscape and cellular heterogeneity in these conditions.Results: This research pinpointed 39 genes exhibiting a robust correlation with efferocytosis in MASH. Among these, five potential diagnostic biomarkers-TREM2, TIMD4, STAB1, C1QC, and DYNLT1-were screened using two distinct machine learning models. Subsequent external validation and animal experimentation validated the upregulation of TREM2 and downregulation of TIMD4 in MASH samples. Notably, both TREM2 and TIMD4 demonstrated area under the curve (AUC) values exceeding 0.9, underscoring their significant potential in facilitating the diagnosis of MASH.Our study comprehensively elucidated the relationship between MASH and efferocytosis, constructing a favorable diagnostic model. Furthermore, we identified potential therapeutic targets for MASH treatment and offered novel insights into unraveling the underlying mechanisms of this disease.

    Keywords: metabolic dysfunction-associated steatohepatitis, Efferocytosis, Bioinformatic analysis, machine learning, TREM2, TIMD4

    Received: 06 Jul 2024; Accepted: 02 Oct 2024.

    Copyright: © 2024 Cao, Liu, Guo, Weng, Chen, Luo, Wang, Zhu, Liu and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Daoquan Peng, Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.